Caralluma fimbriata has been shown to inhibit pre-adipocyte cell division in a mouse cell study published in Food and Nutrition Sciences.
Brand name ingredient Slimaluma, an extract of Caralluma fimbriata, has been shown to inhibit pre-adipocyte cell division in a mouse cell study published in Food and Nutrition Sciences.
According to researchers, “CFE [Caralluma fimbriata extract] appears to inhibit pre-adipocyte cell division by interfering with a mechanism preceding the import of cyclin D1-CDk4/6 complex into the nucleus during the early G1 phase of the cell cycle, suggesting that CFE has the potential to inhibit hyperplastic obesity.”
They said that CFE inhibited 3T3-L1 cell growth in a dose- and duration-dependent manner, with the optimal dose appearing to be at or near 100 µm/ml. One of the researchers was Ramasamy Venkatesh of Gencor Nutrients (Anaheim, CA), the developer of Slimaluma.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
Published: May 14th 2024 | Updated: May 15th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.